Una S Ryan
CIK 1255349 · President & CEO · last filed 2026-10-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CRTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
CHESTNUT HILL, MA 02467
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RNXT | Director | 80,959 | $1.18 | $95.5K | $0 | 8 | 2026-10-02 |
| QNCX | Director | — | $31.73 | — | $0 | 3 | 2025-06-06 |
| Quince Therapeutics, Inc. (CRTX) Delisted | Director | 2,875 | $1.95 | $5.6K | $48.9K | 4 | 2022-06-09 |
| ALBANY MOLECULAR RESEARCH INC (AMRI) Delisted | Director | 51,845 | — | — | $562 | 22 | 2017-05-11 |
| Celldex Therapeutics, Inc. (AVAND) Delisted | President & CEO | — | — | — | $0 | 1 | 2008-03-11 |
Recent Filings · Page 3 of 4
40 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-06-15 | ALBANY MOLECULAR RESEARCH INC (AMRI) Delisted | Grant (A) | +1,126 | $22.5K | EDGAR |
| 2015-03-04 | ALBANY MOLECULAR RESEARCH INC (AMRI) Delisted | Grant (A) | +2,639 | $45.0K | EDGAR |
| 2014-02-06 | ALBANY MOLECULAR RESEARCH INC (AMRI) Delisted | Grant (A) | +3,356 | $35.0K | EDGAR |
| 2013-06-06 | ALBANY MOLECULAR RESEARCH INC (AMRI) Delisted | Grant (A) | +1,434 | $15.0K | EDGAR |
| 2013-02-04 | ALBANY MOLECULAR RESEARCH INC (AMRI) Delisted | Grant (A) | +5,843 | $35.0K | EDGAR |
| 2012-06-14 | ALBANY MOLECULAR RESEARCH INC (AMRI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-06-07 | ALBANY MOLECULAR RESEARCH INC (AMRI) Delisted | Grant (A) | +6,224 | $15.0K | EDGAR |
| 2012-05-23 | ALBANY MOLECULAR RESEARCH INC (AMRI) Delisted | Buy (P) | +200 | $562 | EDGAR |
| 2011-06-09 | ALBANY MOLECULAR RESEARCH INC (AMRI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-06-03 | ALBANY MOLECULAR RESEARCH INC (AMRI) Delisted | Grant (A) | +2,918 | $15.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.